<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344006</url>
  </required_header>
  <id_info>
    <org_study_id>CDA 714703/005</org_study_id>
    <nct_id>NCT00344006</nct_id>
  </id_info>
  <brief_title>Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adolescents in Africa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium
      falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's
      Medicines and Healthcare products Regulatory Agency.

      CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a
      public-private partnership with the Medicines for Malaria Venture (MMV), World Health
      Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical
      Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a
      treatment for acute uncomplicated P. falciparum malaria.

      The combination of chlorproguanil-dapsone-artesunate (CDA) is being developed to supersede
      chlorproguanil-dapsone for the same indication, but the addition of an artemisinin
      derivative, artesunate, should provide additional population benefits over
      chlorproguanil-dapsone alone. The artemisinins have been demonstrated to rapidly reduce
      parasite load and have activity against the sexual stages of the P.falciparum lifecycle. The
      addition of a second agent to the chlorproguanil-dapsone combination should also protect
      against the selection of resistant strains of P.falciparum.

      Artemether-lumefantrine is the only available fixed-dose Artemisinin-based Combination
      Therapy actually available and is considered as the gold standard for the treatment of P.
      falciparum malaria. This study will therefore aim to demonstrate the non-inferiority of the
      combination of CDA to artemether-lumefantrine in terms of efficacy at 28-days. The key
      secondary objectives will compare the Parasite Clearance Times (PCT) and the Fever Clearance
      Times (FCT) between CDA and artemether-lumefantrine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parasitological cure rate, PCR corrected, at day 28 in the PP population The ITT population is a key supportive analysis.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasitological cure rate, PCR-corrected, at day 14 and 42 ACPR, and ACPR PCR corrected at day 14, 28 and 42 Summary of asexual parasite densities on days 0, 1, 2, 3, 7, 14, 28 and 42 by treatment group.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1395</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorproguanil-dapsone-artesunate</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether-lumefantrine</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>chlorproguanil-dapsone-artesunate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Acute, uncomplicated P.falciparum malaria, microscopically confirmed

          -  Temperature at screening of 37.5oC or or more or confirmed history of fever within
             previous 24 hours

          -  Weigh 7.5kg or over

          -  Screening haemoglobin (Hb) of 7g/dl or over, or haematocrit of 25% or more(If Hb not
             available at screening)

          -  Willingness to comply with the study visits and procedures, as outlined in the
             informed consent form

          -  Written or oral witnessed consent has been obtained from parent or guardian

          -  Assent is given by a child aged 12 years or over, in addition to the consent of their
             parent or guardian

        Exclusion criteria:

          -  Features of severe/complicated falciparum malaria

          -  Hypersensitivity to active substances (chlorproguanil, dapsone, artesunate,
             artemether, lumefantrine)

          -  Known allergy to biguanides, sulphones, sulphonamides, artemisinin derived products or
             aminoalcohol drugs

          -  Known history of G6PD deficiency

          -  Infants with a history of hyperbilirubinaemia during the neonatal period

          -  Use of concomitant medications that may induce haemolysis or haemolytic anaemia from
             the WHO (World Health Organization) list of essential drugs

          -  Evidence of any concomitant infection at the time of presentation (including P. vivax,
             P. ovale and P. malariae)

          -  Any other underlying disease that may compromise the diagnosis and the evaluation of
             the response to the study medication (including clinical symptoms of
             immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease)

          -  Malnutrition, defined as a child whose weight-for-height is below -3 standard
             deviations or less than 70% of the median of the NCHS/WHO normalised reference values

          -  Treatment within the past three months with mefloquine or
             mefloquine-sulphadoxine-pyrimethamine; twenty-eight days with
             sulphadoxine/pyrimethamine, sulfalene/pyrimethamine, lumefantrine or
             artemether/lumefantrine, amodiaquine, atovaquone or atovoquone/proguanil,
             halofantrine; 14-days with chlorproguanil/dapsone, or 7-days with quinine (full
             course), proguanil, artemisinins, tetracycline doxycycline or clindamycin

          -  Positive sulphadoxine/pyrimethamine urine screen for 'unknown' antimalarial drug use
             in prior 28-days

          -  Use of an investigational drug within 30 days or 5 half-lives whichever is the longer

          -  Previous participation in this study

          -  Female subjects of child-bearing age, who have had a positive pregnancy test at
             screening, or do not give their consent to take a pregnancy test

          -  Female subjects who will be breast-feeding an infant for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kintampo</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eldoret</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kilifi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barkin Ladi</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calabar</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Enugu</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ifakara</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Ghana</country>
    <country>Kenya</country>
    <country>Nigeria</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>Benin</country>
    <country>Côte D'Ivoire</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria CDA COARTEM Africa pediatrics children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Chlorproguanil</mesh_term>
    <mesh_term>Proguanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CDA 714703/005</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

